• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 15th April 2015

OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020

Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online. Recently published online and free to download in the Journal…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.

Recently published online and free to download in the Journal of Comparative Effectiveness Research is a series of three articles exploring future expectations for new drugs of evidence of relative effectiveness in Europe and comparative effectiveness in the USA in 2020. The articles are co-authored by OHE’s Adrian Towse and Martina Garau, by Donna Messner of the Centre for Medical Technology Policy (CMTP) and Penny Mohr of the Patient-Centered Outcomes Research Institute (PCORI).
 
Patients and those paying for healthcare increasingly want evidence of the additional benefit one treatment offers as compared with another in routine clinical use – termed relative effectiveness in the European Union (EU) and comparative effectiveness in the USA.
 
In the first paper, focussing on the EU, the key factors influencing the future environment for generating and using relative effectiveness evidence are the:
  • degree of EMA use of post-marketing authorization (post-launch) efficacy studies and adaptive licensing;
  • degree of pan-European health technology assessment (HTA) body coordination in reviewing pre-launch evidence and demanding post-launch studies (for example, through the EUnetHTA initiative designed to reduce duplication);
  • nature of regulator – health technology assessment body interaction.

The most likely scenario combining different pathways for these factors entails a dominant role for the regulatory body (EMA) as it becomes more involved in commissioning studies post-launch. This would stimulate further dialogue but not necessarily agreement between companies, HTA bodies and the EMA around post-launch relative effectiveness evidence. In relation to pre-launch requirements, there would be a degree of convergence in requirements as between HTA bodies and a greater dialogue between the EMA and HTA bodies as to what was expected at-launch. Together with some progress in the availability of electronic health records and of pan-European disease registries, there could be a very different expectation of and ability to supply relative effectiveness evidence.

In the second paper, focussing on the USA, the key factors influencing the future environment for generating and using comparative effectiveness evidence are the degree to which: 

  • integration of healthcare delivery occurs;
  • electronic health records are made useful for research purposes;
  • large databases and mixed data sources become tractable for CER and generating new insights;
  • patient involvement in research increases.

​Increased integration of the healthcare system, specifically the degree to which healthcare integration shifts risk acceptance for patient care from payers to provider organisations, is the key driver of the USA scenarios. The USA FDA was not seen as a key driver for change in the USA, unlike the EMA in the EU. No formal FDA policy changes are expected to impact expectations for comparative effectiveness during this period and the FDA was assumed not to coordinate scientific advice for drug developers with payers. In our scenarios, the USA makes greater progress than the EU in creating a data-rich environment and exploring the potential of ‘big data’.

In the third paper, comparing EU and the USA, the authors conclude that drug companies will conduct studies for relative/comparative effectiveness in both the USA and the EU. Companies will want to meet regulator and payer concerns through pre-launch studies where possible. However, an increasingly data-rich environment in the USA could promote use of post-launch observational studies aimed at payers, although the latter retain a strong preference for randomized controlled study evidence to support key elements of value. In Europe, likewise, while there is development in non-experimental methods, multi-country registries, and increased acceptance of observational data by payers and regulators, both prefer randomized controlled studies.

The papers were the results of a research collaboration between OHE and the Center for Medical Technology Policy (CMTP). The papers about EU and USA presenting plausible scenarios of future demand for and ability to produce relative effectiveness and comparative effectiveness evidence used semi-structured key informants interviews and three rounds of modified Delphi. The research was funded by a consortium of five pharmaceutical companies: Amgen, GSK, Lilly, Novartis, and Sanofi.

References:
Towse, A., Garau, M., Mohr, P. and Messner, D.A., 2015.  Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. Journal of Comparative Effectiveness Research, Pages 1-18. Download the full paper here.
 
Messner, D. A., Mohr, P. and Towse, A., 2015. Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. Journal of Comparative Effectiveness Research, Pages 1-16. Download the full paper here.
 
Messner, D. A., Towse, A., Mohr, P. and Garau, M., 2015. The future of comparative effectiveness and relative efficacy of drugs: an international perspective. Journal of Comparative Effectiveness Research, Pages 1-9. Download the full paper here.
 
Related work:
Towse A. Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? OHE Occasional paper 2014.
 
Mestre-Ferrandiz, J., Deverka, P., Pistollato, M. and Rosenberg, E. The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness. OHE Occasional paper 2014.
 
  • Drug Development/R&D
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!